Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Licenses microRNAs From Rockefeller University

NEW YORK (GenomeWeb News) — Rosetta Genomics has struck an agreement to use some of Rockefeller University’s viral and human microRNAs for therapeutic uses, the company said Wednesday.
Rosetta Genomics President and CEO Amir Avniel said the microRNAs offer the company access to more potential drug targets, and is in line with the its strategy to supplement its own research through licensing agreements with key academic centers. 
The company said it now has the rights to more than 500 microRNA targets.
Financial terms of the agreement were not released.
Rosetta Genomics did not specify if this license is an extension of an agreement it signed with Rockefeller a year ago for 180 microRNAs, or if it covers different IP.
That agreement granted Rosetta Genomics rights to use the microRNAs for multiple R&D programs, and called for the company to pay Rockefeller University an initiation fee, maintenance fees, and royalties.
Rosetta Genomics is conducting a liver cancer program through a collaboration with Isis Pharmaceuticals that aims to identify microRNA targets that may be used as therapeutics for the cancer.  
The company’s liver cancer program is funded partly by the Binational Industrial Research and Development Foundation.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.